

HR 113

Triple-Negative Breast Cancer Research and Education Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 4, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 2, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/113>

Sponsor

Name: Rep. Jackson Lee, Sheila [D-TX-18]

Party: Democratic • **State:** TX • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Wilson, Frederica S. [D-FL-24]	D · FL		Feb 4, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 3, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jan 4, 2021)

Triple-Negative Breast Cancer Research and Education Act of 2021

This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors.

Specifically, the National Institutes of Health must conduct and support research into the disease.

Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.

Actions Timeline

- **Feb 2, 2021:** Referred to the Subcommittee on Health.
- **Jan 4, 2021:** Introduced in House
- **Jan 4, 2021:** Referred to the House Committee on Energy and Commerce.